NEIL2 and non-small cell lung carcinoma: Our data showed that IC50 value of NSCLC cells to cisplatin treatment was significantly increased when NEIL2 expression level was upregulated (P < 0.05; Figure 3B), indicating that increased NEIL2 protein level can reduce the sensitivity of NSCLC cells to cisplatin.